CD5 CAR T-Cells (Baylor College of Medicine)

N/A

Report date: 2023/11/28 20:05:47

Base Information

Drug NameCD5 CAR T-Cells (Baylor College of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A